Generalized Myasthenia Gravis Treatment Market Size, Share and Report 2023-2030

Report Overview 

The Global Generalized Myasthenia Gravis Treatment Market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a high CAGR during the forecast period 2023-2030. 

Myasthenia gravis is an autoimmune condition in which antibodies affect the neuromuscular junction, causing intermittent weakness in the muscles responsible for eye movements, facial expressions, speaking, limb movements, and breathing. The estimated prevalence of this condition is 70-300 cases per million individuals worldwide. If left untreated, myasthenia gravis can result in significant disability and recurrent hospital admissions, with an estimated mortality rate of around 2%. 

While many individuals with myasthenia gravis benefit from standard treatments like cholinesterase inhibitors, corticosteroids, and immunosuppressants that reduce the need for steroids (such as azathioprine and mycophenolate mofetil), approximately 8.5-15% of patients still experience varying degrees of disability due to poorly controlled symptoms or unwanted side effects. 

For More Insights Request Free Sample: https://www.datamintelligence.com/download-sample/generalized-myasthenia-gravis-treatment-market 

Market Dynamics 

Elevated Drug Treatment Costs 

The anticipated hindrance to global market expansion during the forecast period is the high cost associated with drug treatment. For instance, AstraZeneca's Soliris therapy comes at an annual price exceeding $650,000 prior to any discounts, making it one of the most expensive drugs in the United States. Following an evaluation by the Institute for Clinical and Economic Review (ICER) regarding its application in treating Myasthenia gravis, concerns have been raised about the drug's affordability. 

Additionally, research indicates that the average annual direct medical expenses per patient range from $760 to $28,780, while hospitalization costs vary between $2,550 and $164,730. The indirect costs associated with the illness are estimated to range from $80 to $3,550. These expenses exhibit significant variations based on patient characteristics, with factors like intravenous immunoglobulin and plasma exchange, myasthenic emergencies, mechanical ventilatory support, and hospitalizations contributing to the direct medical costs of the disease. 

Challenges in Treatment and Adverse Effects 

Obstacles in the treatment of myasthenia gravis, such as long-term side effects from steroids, including osteoporosis, hyperglycemia, cataracts, weight gain, hypertension, and avascular necrosis of the hip, are projected to impede the growth of the global myasthenia gravis treatment market in the forecast period. Furthermore, treatment can result in side effects like chills, dizziness, headaches, and fluid retention, which are also expected to negatively impact the global market's growth during the forecast period. 

Request For Customize Report: https://www.datamintelligence.com/customize/generalized-myasthenia-gravis-treatment-market 

Market Segmentation 

By Drug Class 

• Monoclonal Antibodies 
• Corticosteroids 
• Cholinesterase Inhibitors 
• Immunosuppressants 

By Route of Administration 

• Injectable 
• Oral 

By Distribution Channel 

• Hospital Pharmacies 
• Retail Pharmacies 
• Online Pharmacies 

Market Key Players 

Major players are AstraZeneca, Astellas Pharma, F. Hoffmann-La Roche Ltd., Grifols S.A, Argenx SE, UCB, Harbour Biomed, Lepu Medical Technology (Beijing)Co Ltd, ALEXION PHARMACEUTICALS, INC., and Immunovant Inc. 

Trending Reports 

Mastocytosis Treatment Market 

Lupus Nephritis Treatment Market 

Autoimmune Treatment Market 

Immunology Drugs Market 

Systemic Lupus Erythematosus Market

About Us -

DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

Contact Us -

Name: Sai.k

Designation: Sales & Senior Business Consultant

Email: info@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com